App-Quantinova.ai

An holistic and intergrated approach for investigating the bacterial microbiome, gene expression profile and immune cell profile in the non-muscle invasive bladder cancer tumour microenvironment

Tyler Wooldridge - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Melanocyte-intrinsic PDL1 promotes tumorigenesis and progression in a novel autochthonous melanoma model

Carlos Ontiveros - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Tamoxifen

Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

Celeste Lebbe - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Interferon Gamma

Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

Wade Iams - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

EDP 202

Comprehensive Profiling of B7 Checkpoint Inhibitors and Associated ImmuneResponse in Pancreatic Neuroendocrine Neoplasms (PanNENs)

H. Yan - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors

X. zhang - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

USP8 Deubiquitinates PD-L1 to Suppress the Immunotherapy of Pancreatic Ductal Carcinoma

H. Yang - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

High Expression of CXCR4 - CXCR7 - CXCL12 Predicts Poor Survival after Up-Front Resection of Pancreatic Adenocarcinoma

A. Giardino - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

CXCL12

CITATION Study Protocol: A Prospective Study Aimed to Test the Feasibility of Neoadjuvant Immuno- and Chemo-Therapy in Locally Advanced CCA

A. Belli - International Hepato-Pancreato-Biliary Association (IHPBA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Ticilimumab

Clinical Implication of PD-L1 Expression in Gallbladder Cancer

Y. Sato - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gallbladder cancer

N/A

Involvement of PDL1 and Foxp3 Expression in Human Liver Transplantation Tolerance

N.H. Nam - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PD-L1 induced by lipopolysaccharide via TLR4/MyD88/NF-κB pathway promotes immune escape in pancreatic cancer

W. Wu - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

N/A

Preoperative future liver remnant(FLR) augmentation with local tumor control and in-situ immunization for patients with advanced hepatocellular carcinoma (HCC)

O. Korshak - International Hepato-Pancreato-Biliary Association (IHPBA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Atezolizumab

Oct4/Sox2 DRIVE AN IMMUNOSUPPRESSIVE GSC PHENOTYPE BY INDUCING T-REG EFFECTOR GENES VIA TGFBR2 SIGNALING

Amanda Johnson - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

PD-1 INDEPENDENT OF PD-L1 LIGATION PROMOTES GLIOBLASTOMA GROWTH THROUGH THE NFkB PATHWAY

Reza Mirzaei - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

BIOMARKER IMMUNE CORRELATES IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION

Shiao-Pei Weathers - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Atezolizumab

PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Adilia Hormigo - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548

Michael Weller - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

PRE-CLINICAL ASSESSMENT OF PPRX-1701, A NANOPARTICLE FORMULATION OF 6-BROMO-ACETOXIME, FOR THE TREATMENT OF GLIOBLASTOMA

Mykola Zdioruk - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

tryptophan

LONG TERM STABILIZATION OF RECURRENT HIGH-GRADE GLIOMA WITH PD-1 INHIBITOR PEMBROLIZUMAB IN TWO CASES

Matthew Moldenhauer - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic oligodendroglial tumors

Pembrolizumab

Filters

4177 Abstracts